Literature DB >> 22075083

Nebulized live-attenuated influenza vaccine provides protection in ferrets at a reduced dose.

Jennifer Humberd Smith1, Mark Papania, Darin Knaus, Paula Brooks, Debra L Haas, Raydel Mair, James Barry, S Mark Tompkins, Ralph A Tripp.   

Abstract

Live-attenuated influenza vaccine (LAIV) is delivered to vaccine recipients using a nasal spray syringe. LAIV delivered by this method is immunogenic at current doses; however, improvements in nasal delivery might allow for significant dose reduction. We investigated LAIV vaccination in ferrets using a high efficiency nebulizer designed for nasal delivery. LAIV nasal aerosol elicited high levels of serum neutralizing antibodies and protected ferrets from homologous virus challenge at conventional (10(7)TCID(50)) and significantly reduced (10(3)TCID(50)) doses. Aerosol LAIV also provided a significant level of subtype-specific cross-protection. These results demonstrate the dose-sparing potential of nebulizer-based nasal aerosol LAIV delivery.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22075083      PMCID： PMC3292676          DOI： 10.1016/j.vaccine.2011.10.092

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  36 in total

1.  Comparison of nasal deposition and clearance of aerosol generated by nebulizer and an aqueous spray pump.

Authors:  J D Suman; B L Laube; R Dalby
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

Review 2.  The role of adjuvants in vaccines for seasonal and pandemic influenza.

Authors:  Lorena E Brown
Journal:  Vaccine       Date:  2010-09-17       Impact factor: 3.641

3.  The annual production cycle for influenza vaccine.

Authors:  Catherine Gerdil
Journal:  Vaccine       Date:  2003-05-01       Impact factor: 3.641

4.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses.

Authors:  D Hobson; R L Curry; A S Beare; A Ward-Gardner
Journal:  J Hyg (Lond)       Date:  1972-12

5.  Reactions of antibodies with surface antigens of influenza virus.

Authors:  R G Webster; W G Laver; E D Kilbourne
Journal:  J Gen Virol       Date:  1968-12       Impact factor: 3.891

Review 6.  Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines.

Authors:  R J Cox; K A Brokstad; P Ogra
Journal:  Scand J Immunol       Date:  2004-01       Impact factor: 3.487

7.  The ferret: an animal model to study influenza virus.

Authors:  John A Maher; Joanne DeStefano
Journal:  Lab Anim (NY)       Date:  2004-10       Impact factor: 12.625

8.  Mortality associated with influenza and respiratory syncytial virus in the United States.

Authors:  William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Nancy Cox; Larry J Anderson; Keiji Fukuda
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

Review 9.  Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination.

Authors:  Kenneth M Zangwill; Robert B Belshe
Journal:  Pediatr Infect Dis J       Date:  2004-03       Impact factor: 2.129

10.  Measuring antibody responses to a live attenuated influenza vaccine in children.

Authors:  Min-Shi Lee; Kutubuddin Mahmood; Lopa Adhikary; Marilyn J August; Julie Cordova; Iksung Cho; George Kemble; Keith Reisinger; Robert E Walker; Paul M Mendelman
Journal:  Pediatr Infect Dis J       Date:  2004-09       Impact factor: 2.129
View more
  6 in total

1.  Use of an Open Port Sampling Interface Coupled to Electrospray Ionization for the On-Line Analysis of Organic Aerosol Particles.

Authors:  Kenneth D Swanson; Anne L Worth; Gary L Glish
Journal:  J Am Soc Mass Spectrom       Date:  2017-09-11       Impact factor: 3.109

2.  Respiratory and Intramuscular Immunization With ChAdOx2-NPM1-NA Induces Distinct Immune Responses in H1N1pdm09 Pre-Exposed Pigs.

Authors:  Eleni Vatzia; Elizabeth R Allen; Tanuja Manjegowda; Susan Morris; Adam McNee; Veronica Martini; Reshma Kaliath; Marta Ulaszewska; Amy Boyd; Basudev Paudyal; Veronica B Carr; Tiphany Chrun; Emmanuel Maze; Ronan MacLoughlin; Pauline M van Diemen; Helen E Everett; Teresa Lambe; Sarah C Gilbert; Elma Tchilian
Journal:  Front Immunol       Date:  2021-11-03       Impact factor: 7.561

Review 3.  Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations.

Authors:  Sally A Helmy; Rasha M El-Morsi; Soha A M Helmy; Soha M El-Masry
Journal:  J Drug Deliv Sci Technol       Date:  2022-09-08       Impact factor: 5.062

4.  Development of a murine nose-only inhalation model of influenza: comparison of disease caused by instilled and inhaled A/PR/8/34.

Authors:  Larry E Bowen; Katie Rivers; John E Trombley; J Kyle Bohannon; Shixiong X Li; Jeremy A Boydston; Maryna C Eichelberger
Journal:  Front Cell Infect Microbiol       Date:  2012-05-30       Impact factor: 5.293

Review 5.  Challenges of influenza A viruses in humans and animals and current animal vaccines as an effective control measure.

Authors:  Sung J Yoo; Taeyong Kwon; Young S Lyoo
Journal:  Clin Exp Vaccine Res       Date:  2018-01-29

6.  Distribution of Droplets and Immune Responses After Aerosol and Intra-Nasal Delivery of Influenza Virus to the Respiratory Tract of Pigs.

Authors:  Veronica Martini; Michael Hinchcliffe; Elaine Blackshaw; Mary Joyce; Adam McNee; Peter Beverley; Alain Townsend; Ronan MacLoughlin; Elma Tchilian
Journal:  Front Immunol       Date:  2020-10-27       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.